Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03300596 · ClinicalTrials.gov registry record · NA
Brief New Treatment for Suicide Attempts
A NA study, sponsored by University of Rochester.
- Completed
- Registry status
- NA
- Development phase
- 34
- Enrollment target
NCT03300596: Completed NA study, sponsored by University of Rochester.
NCT03300596 is a NA study that has completed, run by University of Rochester. The registered enrollment target is 34 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03300596, a NA study, has completed, sponsored by University of Rochester.
- COMPLETED
- Registry status
- NA
- Development phase
- 34 participants
- Enrollment target
Study Summary
Individuals with alcohol or drug use problems who are hospitalized for suicide attempt are at high risk for reattempt. This treatment development study adapts a promising outpatient intervention to prevent suicide reattempt in order to administer it during hospitalization to individuals with alcohol and drug use problems, and to test the adapted intervention in a pilot randomized controlled trial.
Primary Outcome
number who reattempt suicide
Interventions
- BEHAVIORAL Enhanced treatment as usual
- BEHAVIORAL Brief intervention to prevent suicide attempt
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2018-03-12 |
| Est. Completion | 2020-09-15 |
| Phase | NA |
What the finished NCT03300596 record still lists
NCT03300596 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which Enhanced treatment as usual is the first listed.
NCT03300596 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03300596 about?
NCT03300596 is a clinical study titled "Brief New Treatment for Suicide Attempts". Individuals with alcohol or drug use problems who are hospitalized for suicide attempt are at high risk for reattempt. This treatment development study adapts a promising outpatient intervention to prevent suicide reattempt in order to administer it during hospitalization to individuals with alcohol...
What is the current status of trial NCT03300596?
This trial is currently completed. It is a NA study. The enrollment target is 34 participants. The study started on 2018-03-12. Estimated completion is 2020-09-15.
What interventions are being tested in trial NCT03300596?
The interventions under investigation include: Enhanced treatment as usual (BEHAVIORAL), Brief intervention to prevent suicide attempt (BEHAVIORAL).
Who is sponsoring clinical trial NCT03300596?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03300596's enrollment target sits among peer trials
34 1570th of 2000 higher than 427 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI